Correspondence
Dr. Jing Ma, Department of Endocrinology and Metabolism, Renji Hospital,
School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Email: majing@renji.com; Phone
number: +86 15800983436
JY and XZ contributed equally to this manuscript.
Keywords: Paxlovid; glycolipid; immunometabolism; SARS-CoV-2
What is already known about this subject?
Paxlovid could reduce the risk of hospitalization or death by 89% as
well as being benefit for immunocompromised and severe COVID-19
patients.
What this study adds?
- The days of viral elimination and inflammation factors, such as IL-6,
IL-10 and interferon-α levels could be lowered by paxlovid.
- Days of viral elimination may be associated with fasting blood
glucose, NK cells count, interferon-α levels.
- Lipids profiles should be monitored before and after treatment of
paxlovid, especially for those who have uncontrolled lipid disorder.
Abstract
A wave of SARS-CoV-2 infection speedily emerged in Shanghai, China,
since late February 2022. Paxlovid is a therapeutic hybrid of different
compounds and a novel SARS-CoV-2 protease inhibitor by blocking an
enzyme required for viral protein synthesis. It could reduce the risk of
hospitalization or death by 89% as well as being benefit for
immunocompromised and severe COVID-19 patients. Our registry study
indicated that the days of viral elimination and inflammation factors,
such as IL-6, IL-10 and interferon-α levels could be lowered by
paxlovid. Days of viral elimination may be associated with fasting blood
glucose, NK cells count, interferon-α levels. Lipids profiles should be
monitored before and after treatment of paxlovid, especially for those
who have uncontrolled lipid disorder.
Introduction
The pandemic arising in the rapid spread of coronavirus disease 2019
(COVID-19) has influenced unparalleled public health emergency
strategies from countries around the world (1). A wave of SARS-CoV-2
infection speedily emerged in Shanghai, China, since late February 2022.
The comprehensive pandemic control strategies in Shanghai are therefore
actually to reduce the number of people infected and to provide early
diagnosis and appropriate treatment for severe COVID-19 (2).
Paxlovid is a therapeutic hybrid of different compounds and a novel
SARS-CoV-2 protease inhibitor by blocking an enzyme required for viral
protein synthesis. Recent studies indicated that it could reduce the
risk of hospitalization or death by 89% as well as being benefit for
immunocompromised and severe COVID-19 patients (3,4).
A meta-analysis indicated that paxlovid did not neither cause the
adverse events nor aggravate the occurrence of adverse events. Its most
common adverse events include nausea, diarrhea, headache, runny nose and
muscle pain (5). Many studies also indicated that hyperglycaemia in
patients with COVID-19 is a strong risk factor of worsening its
prognosis and increasing the possibility of mortality (6,7). However,
whether paxlovid affects the glycolipid immunometabolism in non-severe
COVID-19 patients remains unknown.
Methods
A registry study to estimate the effects of paxlovid on glycolipid and
immunometabolism was launched in South Campus, Renji Hospital from May
10, 2022 to June 7, 2022, with ethics board approval and written
informed consents obtained from all patients. The study was
open-labelled and observational in Shanghai, China (ChiCTR2200059743).
The study protocol was approved by the ethics committees of Renji
Hospital (KY2022-081-A). All the patients enrolled in this study
following the Chinese guidelines (trial version 9 for COVID-19) (8).
They were all treated by paxlovid for five days (day1-day5). Routine
clinical and biochemical data collected from May 10, 2022 to June 7,
2022 and used in this study were their medical history, symptoms,
vaccination status, age, sex, blood pressure, body mass index (BMI),
liver function, kidney function, HbA1c, fasting blood glucose, total
cholesterol, HDL cholesterol, non- HDL cholesterol, LDL cholesterol,
triglycerides, inflammation factors as well as immunometabolism, such as
B lymphocytes, T lymphocytes, Th lymphocytes, Ts lymphocytes. All the
same glycolipid immunometabolism parameters were gained again at day 6
after paxlovid treatment. The Covid-19 virus were tested every day until
both negative for ORF1ab and N genes (Ct value ≥35 by real-time
quantitative PCR) in two consecutive days.
Results
Totally, 64 hospitalized patients with non-severe SARS-CoV-2, with a
mean age of 37 years, a moderate vaccination rate (65.63%) and a low
comorbidity rate (4.69% for diabetes, 6.25% for hypertension, 3.13%
for cancer) were treated by paxlovid (Table S1). Most enrolled patients
with non-severe Covid-19 had different symptoms (20.31% for fever,
20.31% for cough, dizzy for 7.81%, myalgia for 6.25% et al, Table
S1). Our result showed that the mean days of viral elimination treated
by paxlovid was 7.90 ± 2.12, which was consistent with Shuang Ye et
al’results (3). We also found that fasting blood glucose, serum
high-density lipoprotein (HDL), interleukin-6 (IL-6), interleukin-10
(IL-10) and interferon-α were decreased after treatment (allp <0.05, Table 1, Figure 1). At the same time, serum
triglycerides, non-HDL levels and lymphocyte counts, such as B
lymphocytes, T lymphocytes, Th lymphocytes, Ts lymphocytes as well as NK
cells were statistically increased after 5 days treatment (allp <0.05, Table 1, Figure 1).
Next, Cox proportional hazard regression model was used to assess the
association between days of viral elimination and clinical parameters
including the glycolipid immunometabolism factors, and to estimate the
hazard ratios (HRs) and 95% confidence intervals (CIs). We found that
after adjusting for potential confounders, fasting blood glucose, NK
cells count, interferon-α levels before paxlovid treatment and vaccine
were related with days of viral elimination in all participants (Figure
2).
Discussion
This observational study indicated the days of viral elimination and
inflammation factors, such as IL-6, IL-10 and interferon-α levels could
be lowered by paxlovid. Days of viral elimination may be associated with
fasting blood glucose, NK cells count, interferon-α levels and vaccine.
Lipids profiles should be monitored before and after treatment of
paxlovid, especially for those who have uncontrolled lipid disorder.
Compared with placebo, early initiation of Paxlvoid can significantly
reduce the risk of hospitalization or death in mild-to-moderate cases
compared with placebo (9). Paxlovid is recommended for patients with
suitable indications (10), to prevent the disease progression as soon as
possible by early implementation of antiviral therapy to inhibit viral
replication. However, there are no clinical data on its implication in
glycolipid and immunometabolism in adult.
A paxlovid registry study showed that paxlovid prescription within 5
days of diagnosis had a faster clearance of viral load measured by
ORF1ab viral gene replication and a shorter time to viral elimination in
immunocompromised patients. They also indicated that the linear
correlation existed between timing of paxlovid initiation and viral
elimination, which is consistent with our results (3).
Growing evidence indicates that SARS-CoV-2 induces mitochondrial
dysfunction in immune cells. Acute SARS-CoV-2 infection resulted in
rapid mitochondrial dysfunction in both CD4 and CD8 T cells, which
compromised ”T cell” functionality contributing to suppressed ”T cell”
immune responses to viral infection (11). Patients with SARS-CoV-2
infection displayed depolarized mitochondria and abnormal mitochondrial
ultrastructure in monocytes, which was correlated with enhanced
inflammatory responses (12). Our study further indicated that
inflammation status sharply decreased and lymphocyte counts
statistically increased in COVID-19 patients treated by paxlovid. It may
be related to the compromised mitochondrial respiration and increased
HIF-1α expression in alveolar macrophages (AMs) after viral infection in
vivo (13), and the inhibition of pyruvate metabolism by mitochondrial
pyruvate carrier inhibitor (MSDC) enhanced mitochondrial oxidative
phosphorylation (OXPHOS) and fitness, which was associated with the
reduction of proinflammatory cytokines (14). Thus, paxlovid may promote
mitochondrial metabolic fitness and could be a novel therapeutic avenue
for COVID-19.